Exclusive: Altai Capital presses OraSure to sell and give it board seats, letter says

"OraSure is worth significantly more in a sale than as a standalone company," Altai's President and Chief Investment Officer Rishi Bajaj wrote to OraSure's board on Tuesday. "After deducting transaction costs, we estimate OraSure is worth $4.54 to $6.60 per share if sold — a 42% to 109% premium to today's price," Bajaj wrote. OraSure has seen its stock price tumble 73% over the last five years as demand for COVID-19 rapid antigen tests has fallen. Exclusive: Altai Capital presses OraSure to sell and give it ...